Hydroxyurea

Details

Stereochemistry	ACHIRAL
Molecular Formula	CH4N2O2
Molecular Weight	76.0547
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(=O)NO

InChI

InChIKey=VSNHCAURESNICA-UHFFFAOYSA-N

InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

HIDE SMILES / InChI

Description
Sources: https://www.pdr.net/drug-summary/Hydrea-hydroxyurea-888 | https://www.ncbi.nlm.nih.gov/pubmed/24839362

Hydroxyurea is an oral antimetabolite; inhibits ribonucleotide reductase and DNA synthesis. It is used for resistant chronic myeloid leukemia, locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation, and to reduce the frequency of painful crises and the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. Hydroxyurea, a myelosuppressive agent, is the only effective drug proven to reduce the frequency of painful episodes. It raises the level of HbF and the haemoglobin level. It usually decreases the rate of painful episodes by 50%. It was first tested in sickle cell disease in 1984. It also decreases the rate of ACS episodes and blood transfusions by ~50 % in adults. It was developed as an anticancer drug and has been used to treat myeloproliferative syndromes-leukemia, melanoma, and ovarian cancer. It was approved for use by FDA in adults. Side effects includes neutropenia, bone marrow suppression, elevation of hepatic enzymes, anorexia, nausea, vomiting and infertility.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Ribonucleotide reductase 8 Target ID: CHEMBL3301398 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1641648 \| https://www.ncbi.nlm.nih.gov/pubmed/18367739	Inhibitor 8146

Conditions

Condition	Modality	Targets	Highest Phase	Product
Sickle cell anemia 12 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016295s049s050lbl.pdf	Primary		Approved 8307	DROXIA Approved Use DROXIA is an antimetabolite indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises Launch Date -6.53184E10

C_max

Value	Dose	Co-administered	Analyte	Population
793.75 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9473217	2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROXYUREA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
3934 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9473217	2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROXYUREA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.32 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9473217	2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered:		HYDROXYUREA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
40 mg/kg 2 times / day single, oral Highest studied dose Dose: 40 mg/kg, 2 times / day Route: oral Route: single Dose: 40 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17439737	unhealthy, 2-18 years n = 10 Health Status: unhealthy Condition: allogeneic transplantation Age Group: 2-18 years Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/17439737	Sources: https://pubmed.ncbi.nlm.nih.gov/17439737
26.7 mg/kg 1 times / day multiple, oral MTD Dose: 26.7 mg/kg, 1 times / day Route: oral Route: multiple Dose: 26.7 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32472611/	unhealthy, 2-18 years Health Status: unhealthy Condition: sickle cell anemia Age Group: 2-18 years Sources: https://pubmed.ncbi.nlm.nih.gov/32472611/	Sources: https://pubmed.ncbi.nlm.nih.gov/32472611/
20 mg/kg 1 times / day multiple, oral Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf	unhealthy, 2-18 years Health Status: unhealthy Age Group: 2-18 years Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf	Other AEs: Myelosuppression... Other AEs: Myelosuppression Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf
20 mg/kg 1 times / day steady, oral Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01976416	unhealthy n = 104 Health Status: unhealthy Condition: Malaria Population Size: 104 Sources: https://clinicaltrials.gov/ct2/show/NCT01976416	Other AEs: Sudden death, Thrombocytopenia... Other AEs: Sudden death (serious, 1 patient) Thrombocytopenia (below serious, 11 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01976416

AEs

AE	Significance	Dose	Population
Myelosuppression		20 mg/kg 1 times / day multiple, oral Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf	unhealthy, 2-18 years Health Status: unhealthy Age Group: 2-18 years Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf
Thrombocytopenia	below serious, 11 patient	20 mg/kg 1 times / day steady, oral Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01976416	unhealthy n = 104 Health Status: unhealthy Condition: Malaria Population Size: 104 Sources: https://clinicaltrials.gov/ct2/show/NCT01976416
Sudden death	serious, 1 patient	20 mg/kg 1 times / day steady, oral Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01976416	unhealthy n = 104 Health Status: unhealthy Condition: Malaria Population Size: 104 Sources: https://clinicaltrials.gov/ct2/show/NCT01976416

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532	inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1401 BCRP 678 OATP1B1 770 OATP1B3 691 BSEP 392 MRP2 363 MRP3 156 MRP4 202 CYP1A2 1463 CYP2A6 670 CYP2C19 1410 CYP2E1 846	OATP1B3 333 OATP1A2 59 OATP1B1 389 OCTN1 47 OCTN2 50 CYP 252	P-gp 252

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2D6 1826	inhibitor 3185 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000127071, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978168/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDY3In19	likely [IC50 >10 uM]	yes (pharmacogenomic study) Comment: Of the 73 children completing the study, 42 had reduced-functioning alleles; 82% of the 27 children taking hydoxyurea had reduced-functioning alleles, versus 47% of 36 those with mild disease (P < .05). Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000127071, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978168/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDY3In19
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17180388/, https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDY3In19	no [Activation 39.8107 uM]
CYP1A2 1620	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQ2NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 702	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQ2NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1484	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQ2NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQ2NyJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 929	inhibitor 3185 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQ2NyJ9fQ%3D%3D	no [IC50 >10 uM]
BSEP 393	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 452	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 206	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 235	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
BCRP 751	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17180388/	no
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17180388/	no
OATP1B1 785	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 700	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
P-gp 1588	inducer 1515 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000127071, https://pubmed.ncbi.nlm.nih.gov/1550597/	yes

Drug as victim

Target	Modality	Activity
CYP 252	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/19817872/	no
OATP1A2 59	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21256917/	weak
OATP1B1 389	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21256917/	weak
OCTN1 47	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21256917/	weak
OCTN2 50	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21256917/	weak
OATP1B3 333	substrate 3264 Sources: https://bioinformatics.charite.de/transformer/index.php?site=fullinfo&cname=000127071, https://pubmed.ncbi.nlm.nih.gov/21256917/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDY3In19

PubMed

Title	Date	PubMed
Hydroxyurea-induced neurotoxicity in HIV disease.	1999 Aug 20	10465092
Dibutyryl cyclic AMP-induced enhancement of RB protein degradation in human hepatoma cells.	1999 Nov-Dec	10697531
Senescence-like changes induced by hydroxyurea in human diploid fibroblasts.	2000 Aug	10978678
Ser45 plays an important role in managing both the equilibrium and transition state energetics of the streptavidin-biotin system.	2000 May	10850797
Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.	2000 Nov 1	11115955
[Low-dose cytosine-arabinoside (Ara-C) therapy for chronic myeloid leukemia].	2001	11317537
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?	2001	11285159
Hydroxyurea-induced oxidative damage of normal and sickle cell hemoglobins in vitro: amelioration by radical scavengers.	2001	11170226
Stroke prevention and treatment in sickle cell disease.	2001 Apr	11295986
Chromosomal aberrations in lymphocytes of employees in transformer and generator production exposed to electromagnetic fields and mineral oil.	2001 Apr	11255210
The anti-malarial artesunate is also active against cancer.	2001 Apr	11251172
A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate.	2001 Apr	11241357
The Saccharomyces cerevisiae phosphotyrosyl phosphatase activator proteins are required for a subset of the functions disrupted by protein phosphatase 2A mutations.	2001 Apr 1	11262194
Cell cycle expression of histone genes in Trypanosoma cruzi.	2001 Apr 6	11295175
Induction of unscheduled DNA synthesis in hairless mouse epidermis by 8-methoxypsoralen plus ultraviolet A (PUVA).	2001 Feb	11255790
Foraging behaviour in Drosophila larvae: mushroom body ablation.	2001 Feb	11238255
Sickle cell anemia and antisickling agents then and now.	2001 Feb	11172667
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor.	2001 Feb	11168991
Leukotriene modifiers in pediatric asthma management.	2001 Feb	11158473
Dynamic changes in subnuclear NP95 location during the cell cycle and its spatial relationship with DNA replication foci.	2001 Feb 15	11161719
A novel genetic screen identifies checkpoint-defective alleles of Schizosaccharomyces pombe chk1.	2001 Jan	11270571
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.	2001 Jan	11243402
Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study.	2001 Jan	11243396
Current management in polycythemia vera.	2001 Jan	11242599
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.	2001 Jan	11233781
Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.	2001 Jan	11233778
Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2.2.15 cells.	2001 Jan	11211885
Cell division activity during apical hook development.	2001 Jan	11154331
Requirement for three novel protein complexes in the absence of the Sgs1 DNA helicase in Saccharomyces cerevisiae.	2001 Jan	11139495
Relative resistance in the development of T cell anergy in CD4+ T cells from simian immunodeficiency virus disease-resistant sooty mangabeys.	2001 Jan 1	11123330
De novo activation of the beta-phaseolin promoter by phosphatase or protein synthesis inhibitors.	2001 Jan 19	11031270
[Hydroxyurea--is it a harmless drug in Vaquez disease?]].	2001 Mar	11317962
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.	2001 Mar	11317960
Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders.	2001 Mar	11317958
Clinical predictors of health-related quality of life depend on asthma severity.	2001 Mar	11282767
Limbal stem cell deficiency arising from systemic chemotherapy.	2001 Mar	11277104
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients.	2001 Mar	11260078
The Saccharomyces cerevisiae MUM2 gene interacts with the DNA replication machinery and is required for meiotic levels of double strand breaks.	2001 Mar	11238403
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.	2001 Mar	11237055
A unique, complex variant philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia.	2001 Mar	11231500
Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW264 cells.	2001 Mar 23	11264004
N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase.	2001 Mar 26	11277534
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.	2001 Mar 30	11316999
The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression.	2001 Mar 9	11257228
Involvement of pRB-related p107 protein in the inhibition of S phase progression in response to genotoxic stress.	2001 May 18	11278582

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Chronic Myelogenous Leukemia 15 mg/kg/day orally as a single dose Usual Adult Dose for Head and Neck Cancer 15 mg/kg/day orally as a single dose Usual Adult Dose for Sickle Cell Anemia 15 mg/kg orally once a day; increase 5 mg/kg/day every 12 weeks Maximum dose: 35 mg/kg/day Usual Pediatric Dose for Sickle Cell Anemia 2 years and older: 20 mg/kg orally once a day; increase 5 mg/kg/day every 8 weeks or if a painful crisis occurs; increase dosing only if blood counts are in the acceptable range; do not increase dosing if myelosuppression occurs; if blood counts are considered toxic, discontinue therapy until hematologic recovery Duration of therapy: Give until mild myelosuppression (absolute neutrophil count 2000/microliter to 4000/microliter) is achieved, up to 35 mg/kg/day Maximum dose: 35 mg/kg/day

Route of Administration: Oral

Name

Type

Language

Hydroxyurea

Official Name

English

HYDROXYUREA [HSDB]

Common Name

English

SIKLOS

Brand Name

English

Hydroxycarbamide [WHO-DD]

Common Name

English

SQ 1089

Code

English

HYDREA

Brand Name

English

HYDROXYCARBAMIDE [EMA EPAR]

Common Name

English

HYDROXYCARBAMIDE

Official Name

English

HYDROXYUREA [VANDF]

Common Name

English

SQ-1089

Code

English

UREA, HYDROXY-

Systematic Name

English

hydroxycarbamide [INN]

Common Name

English

HYDROXYUREA [IARC]

Common Name

English

HYDROXYUREA [USP-RS]

Common Name

English

HYDROXYUREA [USP MONOGRAPH]

Common Name

English

DROXIA

Brand Name

English

HYDROXYCARBAMIDE [EP MONOGRAPH]

Common Name

English

HYDROXYCARBAMIDE [JAN]

Common Name

English

NSC-32065

Code

English

HYDROXYUREA [MI]

Common Name

English

HYDROXYUREA [ORANGE BOOK]

Common Name

English

HYDROXYUREA [USAN]

Common Name

English

HYDROXYCARBAMIDE [MART.]

Common Name

English

Classification Tree Code System Code

WHO-ESSENTIAL MEDICINES LIST

8.2